These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


120 related items for PubMed ID: 346616

  • 1. Effects of halofenate on glucose tolerance in patients with hyperlipoproteinemia.
    Feldman EB, Gluck FB, Carter AC.
    J Clin Pharmacol; 1978; 18(5-6):241-8. PubMed ID: 346616
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The metabolic spectrum of halofenate.
    Ryan JR.
    Int J Clin Pharmacol Biopharm; 1975 Jul; 12(1-2):239-43. PubMed ID: 51838
    [Abstract] [Full Text] [Related]

  • 4. One-year trials with halofenate, clofibrate, and placebo.
    Dujovne CA, Azarnoff DL, Huffman DH, Pentikäinen P, Hurwitz A, Shoeman DW.
    Clin Pharmacol Ther; 1976 Mar; 19(3):352-9. PubMed ID: 177242
    [Abstract] [Full Text] [Related]

  • 5. Comparison of clofibrate with halofenate in diabetics with hyperlipidaemia.
    Krut LH, Seftel HC, Joffe BI.
    S Afr Med J; 1977 Mar 12; 51(11):348-52. PubMed ID: 323994
    [Abstract] [Full Text] [Related]

  • 6. A two-year crossover therapeutic trial with halofenate and clofibrate.
    Dujovne CA, Azarnoff DL, Pentikainen P, Manion C, Hurwitz A, Hassanein K.
    Am J Med Sci; 1976 Mar 12; 272(3):277-84. PubMed ID: 797258
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Halofenate in the treatment of type II hyperlipoproteinemia. Double blind comparison with clofibrate.
    Rees ED, Hamilton RD, Kanner IF, Wasson S, Hearn T.
    Atherosclerosis; 1976 Sep 12; 24(3):537-46. PubMed ID: 788722
    [Abstract] [Full Text] [Related]

  • 9. A double-blind comparison of the hypolipidemic and hypouricemic action of halofenate and clofibrate in patients with hyperlipoproteinemia (types III, IV and V).
    Neuman J, de Neuman MP, Talmasky S, Pesce R, Valero E, Martiarena JL.
    J Cardiovasc Surg (Torino); 1973 Sep 12; Spec No():532-7. PubMed ID: 4377715
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effects of halofenate and probenecid on serum lipids and uric acid in hyperlipidemic, hyperuricemic adults.
    Bassett DR, Mikkelsen WM, Buckingham RB, Block WD, Sidiq M, Shakibai A, DiGaetano R, Liou LL.
    Clin Pharmacol Ther; 1977 Sep 12; 22(3):340-51. PubMed ID: 330079
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.
    Ferrari C, Frezzati S, Romussi M, Bertazzoni A, Testori GP, Antonini S, Paracchi A.
    Metabolism; 1977 Feb 12; 26(2):129-39. PubMed ID: 834147
    [Abstract] [Full Text] [Related]

  • 14. [Effect of halofenate on triglyceride and uric acid levels, coagulation and platelet behaviour in patients with hyperlipoproteinemia type IV and hyperuricemia (author's transl)].
    Kuntzen O, Hehl FJ, Walter E, Zimmermann R.
    Arzneimittelforschung; 1978 Feb 12; 28(12):2349-52. PubMed ID: 227420
    [Abstract] [Full Text] [Related]

  • 15. Effect of halofenate on serum uric acid.
    Aronow WS, Harding PR, Khursheed M, Vangrow JS, Papageorge's NP.
    Clin Pharmacol Ther; 1973 Feb 12; 14(3):371-3. PubMed ID: 4572799
    [No Abstract] [Full Text] [Related]

  • 16. Studies on the mechanism of action of halofenate.
    Mandel LR.
    Lipids; 1977 Jan 12; 12(1):34-43. PubMed ID: 319318
    [Abstract] [Full Text] [Related]

  • 17. Altered insulin and glucagon secretion in treated genetic hyperlipemia: a mechanism of theraphy?
    Eaton RP, Oase R, Schade DS.
    Metabolism; 1976 Mar 12; 25(3):245-9. PubMed ID: 1250161
    [Abstract] [Full Text] [Related]

  • 18. Hepatic triglyceride lipases--effect of clofibrate and halofenate.
    Cenedella RJ.
    Biochem Pharmacol; 1976 Dec 01; 25(23):2657-61. PubMed ID: 10929
    [No Abstract] [Full Text] [Related]

  • 19. The uricosuric action of halofenate (MK-185) in patients with hyperuricemia or uncomplicated primary gout and hyperlipidemia.
    Hutchison JC, Wilkinson WH.
    Atherosclerosis; 1973 Dec 01; 18(3):353-62. PubMed ID: 4584481
    [No Abstract] [Full Text] [Related]

  • 20. Potentiation of hypoglycemic effect of chlorpropamide and phenfromin by halofenate.
    Kudzma DJ, Friedberg SJ.
    Diabetes; 1977 Apr 01; 26(4):291-5. PubMed ID: 321288
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 6.